Patents Assigned to Meiji Seika Pharma Co., Ltd.
-
Publication number: 20130345087Abstract: The present invention relates to a method for obtaining cells or cell populations having a high biological activity from a biological tissue by enzymatic isolation, and probes for use in the method; more specifically to a method for analyzing a biological tissue, comprising applying two or more probes respectively containing biological-component binding domains through which two or more proteins bind to a predetermined biological component, to an isolated biological tissue, and analyzing binding amounts of the probes to the biological tissue.Type: ApplicationFiled: March 15, 2012Publication date: December 26, 2013Applicants: MEIJI SEIKA PHARMA CO., LTD., TOHOKU UNIVERISTYInventors: Youhei Yamagata, Masafumi Goto, Kimiko Watanabe
-
Patent number: 8568710Abstract: A plant disease controlling agent containing a lactic acid bacterium which is capable of controlling plant disease and a plant disease controlling method which comprises treating a plant and/or soil with the above-mentioned lactic acid bacterium. By using the lactic acid bacterium seemingly advantageous to human health, an agricultural crop can be safely and stably produced. As the lactic acid bacterium as mentioned above, use may be favorably made of a microorganism belonging to the genus Pediococcus such as Pediococcus pentosaceus or a microorganism belonging to the genus Lactobacillus such as Lactobacillus plantarum.Type: GrantFiled: July 28, 2005Date of Patent: October 29, 2013Assignee: Meiji Seika Pharma Co., Ltd.Inventors: Kazuhisa Tsuda, Yoshitaka Kosaka, Mitsunobu Kataoka
-
Patent number: 8569033Abstract: A method for suppressing a reduction in an endoglucanase activity in the presence of a surfactant, characterized by modifying a protein having the endoglucanase activity in which the N-terminus is an amino acid other than pyroglutamic acid, to a protein having the N-terminus of pyroglutamic acid, is disclosed. Further, a modified protein having an endoglucanase activity wherein the N-terminal amino acid is converted into pyroglutamic acid by an amino acid modification, a polynucleotide encoding the protein, an expression vector comprising the polynucleotide, a host cell transformed with the expression vector, and a process for producing the protein by cultivating the host cell, are disclosed.Type: GrantFiled: December 7, 2004Date of Patent: October 29, 2013Assignee: Meiji Seika Pharma Co., Ltd.Inventors: Manabu Watanabe, Koji Yanai, Yumiko Tsuyuki
-
Patent number: 8541394Abstract: This invention relates to novel aminoglycoside antibiotics, which have potent antimicrobial activity against bacteria, which induce infectious diseases, particularly MRSA, and has no significant nephrotoxicity, and process for producing them. More particularly, the present invention relates to compounds represented by formula (Ia) or their pharmacologically acceptable salts or solvates, or their diastereomer mixtures, antimicrobial agents comprising them, and a process for producing them.Type: GrantFiled: March 7, 2012Date of Patent: September 24, 2013Assignees: Meiji Seika Pharma Co., Ltd., Microbial Chemistry Research FoundationInventors: Yoshihiko Kobayashi, Yoshihisa Akiyama, Takeshi Murakami, Nobuto Minowa, Masaki Tsushima, Yukiko Hiraiwa, Shoichi Murakami, Mitsuhiro Abe, Kazushige Sasaki, Shigeru Hoshiko, Toshiaki Miyake, Yoshiaki Takahashi, Daishiro Ikeda
-
Publication number: 20130245271Abstract: An objective of the present invention is to provide a process for producing 4-carbonyl oxyquinoline derivatives useful as agricultural and horticultural pesticides and fungicides. The objective can be attained by a process for producing 4-carbonyl oxyquinoline derivatives represented by general formula (1), the process including reacting a quinolone derivative with a halogenated compound or an acid anhydride in the presence of a phase transfer catalyst and a base.Type: ApplicationFiled: November 16, 2011Publication date: September 19, 2013Applicants: MEIJI SEIKA PHARMA CO., LTD., NIPPON KAYAKU CO., LTD.Inventors: Shizuo Shimano, Akinori Morikawa, Kenichi Yamamoto, Hiroki Hotta, Kazumi Yamamoto, Nozomu Nakanishi, Nobuto Minowa
-
Publication number: 20130217663Abstract: An object of the present invention is to provide a compound having a modulating activity at an S1P receptor which is useful for preventing and treating autoimmune diseases, allergic diseases, and the like. According to the present invention, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof is provided.Type: ApplicationFiled: December 21, 2012Publication date: August 22, 2013Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventor: MEIJI SEIKA PHARMA CO., LTD.
-
Patent number: 8481779Abstract: Provided is a method for producing a compound expressed by the following formula (3): [where R1 represents a hydrogen atom or C1-4 alkyl group, and R2 represents C1-4 alkyl group, C1-4 alkoxy group, aryl group, aryloxy group or benzyloxy group], the method comprising a reaction of dehydro-condensing a compound expressed by the following formula (1) and a compound expressed by the following formula (2): while being converted to a desired geometric isomer in the presence or absence of an acid catalyst, under a condition that an organic solvent to be used for the reaction is a mixed solvent of acetic acid and a solvent selected from the group consisting of toluene, xylene and chlorobenzene.Type: GrantFiled: June 14, 2011Date of Patent: July 9, 2013Assignee: Meiji Seika Pharma Co., Ltd.Inventors: Takashi Ando, Nobuto Minowa, Masaaki Mitomi
-
Publication number: 20130165482Abstract: Specific amine derivatives have been found to possess excellent activities as pest control agents.Type: ApplicationFiled: August 26, 2011Publication date: June 27, 2013Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Shinzo Kagabu, Masaaki Mitomi, Shigeki Kitsuda, Ryo Horikoshi, Masahiro Nomura, Yasumichi Onozaki
-
Publication number: 20130150414Abstract: Specific amine derivatives have been found to possess excellent activities as pest control agents.Type: ApplicationFiled: February 7, 2013Publication date: June 13, 2013Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Shinzo KAGABU, Masaaki MITOMI, Shigeki KITSUDA, Ryo HORIKOSHI, Masahiro NOMURA, Yasumichi ONOZAKI
-
Patent number: 8440400Abstract: The present invention relates to a process for efficiently amplifying a giant DNA. More particularly, the present invention relates to a process for amplifying DNA in a cell, comprising amplifying the DNA as the target of amplification in the presence of DNAs selected from the following (i), (ii) and (iii): (i) DNA encoding a protein selected from the following 1), 2) and 3): 1) a protein consisting of the amino acid sequence of SEQ ID NO: 1, 2) a protein comprising an amino acid sequence which has a deletion, substitution, insertion or addition of one or more amino acids in the amino acid sequence of SEQ ID NO: 1, and 3) a protein comprising an amino acid sequence which has an identity of 90% or more to the amino acid sequence of SEQ ID NO: 1, (ii) DNA consisting of the nucleotide sequence of SEQ ID NO: 2, and (iii) DNA hybridizing to the nucleotide sequence of SEQ ID NO: 2 under stringent conditions.Type: GrantFiled: June 5, 2009Date of Patent: May 14, 2013Assignee: Meiji Seika Pharma Co., Ltd.Inventors: Takeshi Murakami, Naomi Sumida, Koji Yanai
-
Publication number: 20130116416Abstract: Disclosed are a ketoreductase mutant which can be used for an efficient production of daunorubicin derivatives, a DNA encoding the mutant, a transformant prepared by introducing the DNA thereinto to produce a daunorubicin derivative, and a process of producing a daunorubicin derivative using the transformant. The ketoreductase mutant has an amino acid sequence in which one amino acid residue or two or more amino acid residues selected from the group consisting of amino acids located at positions corresponding to the 42nd, 149th, 153rd, 270th, and 306th amino acids in the amino acid sequence of a ketoreductase (EvaE) from a chlororemomycin-producing bacterium (Amycolatopsis orientalis) are substituted with another amino acid residues.Type: ApplicationFiled: May 21, 2010Publication date: May 9, 2013Applicant: MEIJI SEIKA PHARMA, CO., LTD.Inventors: Fusuke Mazuka, Takayoshi Fukushima, Naomi Sumida, Koji Yanai
-
Publication number: 20130102637Abstract: Provided is a novel pest control agent using at least one imino derivative represented by the following chemical formula (I):Type: ApplicationFiled: July 4, 2011Publication date: April 25, 2013Applicants: GIFU UNIVERSITY, MEIJI SEIKA PHARMA CO., LTD.Inventors: Shinzo Kagabu, Masaaki Mitomi, Shigeki Kitsuda, Masahiro Nomura, Satoshi Nakamura, Kazumi Yamamoto
-
Patent number: 8383392Abstract: Disclosed is a transformant prepared by introducing a ketoreductase gene involved in the biosynthesis of L-epivancosamine into an actinobacterium originally capable of producing daunorubicin. Also disclosed is a process of efficiently producing a non-natural daunorubicin derivative using the transformant. The transformant is capable of efficiently producing a non-natural daunorubicin derivative such as epidaunorubicin.Type: GrantFiled: September 12, 2008Date of Patent: February 26, 2013Assignee: Meiji Seika Pharma Co., Ltd.Inventors: Naomi Sumida, Manabu Watanabe, Koji Yanai
-
Publication number: 20130045207Abstract: Provided is a novel antibody having an excellent antibacterial activity against P. aeruginosa. By using plasmablasts obtained from cystic fibrosis patients with chronic P. aeruginosa pulmonary infection as starting materials, antibodies which bind to LPS of a P. aeruginosa strain of serotype G and which have excellent antibacterial activities in vitro and in vivo were successfully obtained.Type: ApplicationFiled: February 18, 2011Publication date: February 21, 2013Applicants: SYMPHOGEN A/S, MEIJI SEIKA PHARMA CO., LTD.Inventors: Jiro Tanaka, Peter Sejer Andersen, Takafumi Okutomi, Tsuneyoshi Inaba, Keiko Otsuka, Hirotomo Akabane, Yukari Hoshina, Hiroshi Nagaso, Masashi Kumagai
-
Patent number: 8367707Abstract: Disclosed is a composition for use as a pest control agent, comprising a compound represented by formula (I) or an agriculturally and horticulturally acceptable salt thereof as active ingredient and an agriculturally and horticulturally acceptable carrier:Type: GrantFiled: October 13, 2010Date of Patent: February 5, 2013Assignees: Meiji Seika Pharma Co., Ltd., The Kitasato InstituteInventors: Kimihiko Goto, Ryo Horikoshi, Mariko Tsuchida, Kazuhiko Oyama, Satoshi Omura, Hiroshi Tomoda, Toshiaki Sunazuka
-
Patent number: 8367833Abstract: Disclosed is a process for producing 6-aryloxyquinoline derivatives useful as insecticides or fungicides for agricultural and horticultural use. The process comprises a cyclization reaction step of reacting an anthranilic acid derivative represented by general formula (1) with a kenone in the presence of an acid to obtain a quinolone derivative and a condensation reaction step of reacting the quinolone derivative with a halogen compound or an acid anhydride to obtain a quinoline derivative.Type: GrantFiled: July 13, 2009Date of Patent: February 5, 2013Assignees: Nippon Kayaku Co., Ltd., Meiji Seika Pharma Co., Ltd.Inventors: Yasuhito Kato, Shizuo Shimano, Akinori Morikawa, Hiroki Hotta, Kazumi Yamamoto, Nozomu Nakanishi, Nobuto Minowa, Hiroshi Kurihara
-
Publication number: 20130023014Abstract: An object is to identify endoglucanase and ?-glucosidase genes by isolating genomic DNA containing cellulase genes, which are classified into endoglucanases or ?-glucosidases, from Acremonium cellulolyticus, and sequencing the nucleotide sequences thereof. The inventors intensively compared the amino acid sequences of known endoglucanases and ?-glucosidases with each other to find conserved region of amino acid sequences in Acremonium cellulolyticus, and various primers were designed based on the information. PCR was carried out using the various primers thus designed and genomic DNA or cDNA as a template. As a result, gene fragments of endoglucanases and ?-glucosidases were obtained. Primers were designed based on the gene fragments, and PCR was carried out to amplify nine genes of endoglucanases and ?-glucosidases. The nucleotide sequences thereof were sequenced, and the present invention was completed.Type: ApplicationFiled: March 31, 2010Publication date: January 24, 2013Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventor: Fumikazu Yokoyama
-
Publication number: 20130022604Abstract: Provided is a novel antibody having an excellent antibacterial activity against P. aeruginosa. By using plasmablasts obtained from cystic fibrosis patients with chronic P. aeruginosa pulmonary infection as starting materials, antibodies which bind to LPS of a P. aeruginosa strain of serotype B and which have excellent antibacterial activities in vitro and in vivo were successfully obtained.Type: ApplicationFiled: February 18, 2011Publication date: January 24, 2013Applicants: SYMPHOGEN A/S, MEIJI SEIKA PHARMA CO., LTD.Inventors: Jiro Tanaka, Peter Sejer Andersen, Takafumi Okutomi, Tsuneyoshi Inaba, Keiko Otsuka, Hirotomo Akabane, Yukari Hoshina, Hiroshi Nagaso, Masashi Kumagai
-
Publication number: 20130004500Abstract: Provided is a novel antibody having an excellent antibacterial activity against P. aeruginosa. By using plasmablasts obtained from cystic fibrosis patients with chronic P. aeruginosa pulmonary infection as starting materials, antibodies which bind to LPS of a P. aeruginosa strain of serotype A and which have excellent antibacterial activities in vitro and in vivo were successfully obtained.Type: ApplicationFiled: February 18, 2011Publication date: January 3, 2013Applicants: SYMPHOGEN A/S, MEIJI SEIKA PHARMA CO., LTD.Inventors: Jiro Tanaka, Peter Sejer Andersen, Takafumi Okutomi, Tsuneyoshi Inaba, Keiko Otsuka, Hirotomo Akabane, Yukari Hoshina, Hiroshi Nagaso, Masashi Kumagai
-
Publication number: 20130004499Abstract: Provided is a novel antibody having an excellent antibacterial activity against P. aeruginosa. By using plasmablasts obtained from cystic fibrosis patients with chronic P. aeruginosa pulmonary infection as starting materials, antibodies which bind to LPS of a P. aeruginosa strain of serotype E and which have excellent antibacterial activities in vitro and in vivo were successfully obtained.Type: ApplicationFiled: February 18, 2011Publication date: January 3, 2013Applicants: SYMPHOGEN A/S, Meiji Seika Pharma Co., Ltd.Inventors: Jiro Tanaka, Peter Sejer Andersen, Takafumi Okutomi, Tsuneyoshi Inaba, Keiko Otsuka, Hirotomo Akabane, Yukari Hoshina, Jun Saito, Hiroshi Nagaso, Masashi Kumagai, Yasuyo Hagiwara